A 48-weeks national multicenter randomized open clinical trial evaluating tolerance and efficacy of a treatment simplification by lopinavir/ritonavir versus continuation of current treatment in HIV-infected patients with a viral load inferior to 50 copies/mL since 6 months at least

Trial Profile

A 48-weeks national multicenter randomized open clinical trial evaluating tolerance and efficacy of a treatment simplification by lopinavir/ritonavir versus continuation of current treatment in HIV-infected patients with a viral load inferior to 50 copies/mL since 6 months at least

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2013

At a glance

  • Drugs Antiretrovirals; Lopinavir/ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms KALESOLO
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Sep 2010 Results have been published in the Journal of Antimicrobial Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top